Company news
Ani Pharmaceuticals, Inc. (NASDAQ:ANIP) news
Every Ani Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
August 24, 2026
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
August 7, 2026
ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET
July 24, 2026
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
July 16, 2026
ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluo...
July 13, 2026
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
May 27, 2026
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
May 8, 2026
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
April 24, 2026
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
April 20, 2026
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
April 13, 2026
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
April 8, 2026
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
April 7, 2026
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
February 27, 2026
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
February 13, 2026
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
January 12, 2026
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
December 2, 2025
ANI Pharmaceuticals Announces Board Transition
December 1, 2025
ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London
November 11, 2025
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
November 7, 2025
ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
October 24, 2025
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy o...
October 16, 2025
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
August 25, 2025
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
August 8, 2025
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
August 1, 2025
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
July 23, 2025
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
July 2, 2025
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
June 12, 2025
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
May 27, 2025
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
May 22, 2025
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
May 12, 2025
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
May 9, 2025
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveit...
May 5, 2025
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET
April 9, 2025
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
March 31, 2025
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
March 19, 2025
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ®
March 18, 2025
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label
March 14, 2025
ANI Pharmaceuticals Announces FDA Approval of New Purified Cortrophin Gel® Prefilled Syringe
March 3, 2025
ANI Pharmaceuticals Reports Record Fourth Quarter and Full-Year 2024 Financial Results and Raises 2025 Guidance
February 28, 2025
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March
February 19, 2025
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET
February 18, 2025
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference
January 28, 2025
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook
January 13, 2025
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity
January 2, 2025
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 30, 2024
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance
November 8, 2024
ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in N...
November 4, 2024